CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas

CytomX Therapeutics is teaming up with Astellas Pharma in a research and development alliance focused on developing new cancer immunotherapies based on its antibody technology. Under deal terms announced late Monday, Astellas is paying CytomX (NASDAQ: CTMX) $80 million up front. South San Francisco-based CytomX will conduct and finance the research up to the selection […]

Click to view original post